For the quarter ending 2025-09-30, AVIR made $49,482K in revenue. -$41,848K in net income. Net profit margin of -84.57%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 38,347 | 32,275 | 39,314 | 26,159 |
| General and administrative | 7,220 | 9,070 | 12,602 | 11,043 |
| Total operating expenses | 45,567 | 41,345 | 51,916 | 37,202 |
| Loss from operations | -45,567 | -41,345 | -51,916 | -37,202 |
| Interest income and other, net | 3,714 | 4,391 | 6,404 | 6,277 |
| Loss before income taxes | -41,853 | -36,954 | -45,512 | -30,925 |
| Income tax expense | 196 | 207 | 233 | 226 |
| Net loss | -42,049 | -37,161 | -45,745 | -31,151 |
| Unrealized gain on available-for-sale investments | 201 | -81 | -298 | 921 |
| Comprehensive loss | -41,848 | -37,242 | -46,043 | -30,230 |
| Net loss per share - basic | -0.53 | -0.44 | -0.543 | -0.37 |
| Net loss per share - diluted | -0.53 | -0.44 | -0.543 | -0.37 |
| Weighted-average number of common shares - basic | 79,052,154 | 83,747,335 | -52,428.333 | 84,422,000 |
| Weighted-average number of common shares - diluted | 79,052,154 | 83,747,335 | -52,428.333 | 84,422,000 |
Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. (AVIR)